Bionano Genomics, Inc. (BNGO): M&A transaction — Bionano completes acquisition of Purigen Biosystems for $32M cash, plus $32M earnout

Bionano Genomics, Inc.

Closed acquisition of Purigen Biosystems on Nov 30, 2022; upfront cash consideration ~$32M.
Up to additional $32M in cash payable upon achievement of certain milestones.
Purigen survives as a wholly owned subsidiary of Bionano Genomics.
Consideration subject to customary adjustments for cash, debt, transaction expenses, and net working capital.
Post-closing purchase price adjustment mechanism with escrow for potential adjustments.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 1.0

Bionano Genomics, Inc. completed an acquisition involving Purigen Biosystems, Inc. for approximately $32.0 million in cash (closed 2022-11-30).

Action: acquisition
Counterparty: Purigen Biosystems, Inc.
Consideration: approximately $32.0 million in cash
Closing: 2022-11-30

Exact text from the filing

the surviving corporation of the Merger and a wholly owned subsidiary of the Company. Pursuant to the Merger, the Company paid at closing upfront consideration of approximately $32.0 million in cash. The upfront consideration was subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and net working capital relative to

View on SEC.gov

Browse all m&a transactions →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-043729

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.